// App-Quantinova.ai

670 : Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Nicola Goekbuget

Principal Investigators

  • Gerhard Zugmaier

  • Monika Brueggemann

  • Matthias Ritgen

  • Petra Klappers

  • Noemi Mergen

  • Marie-Elisabeth Goebeler

  • Hermann Einsele

  • Ralf Bargou

  • Andreas Viardot

  • Matthias Stelljes

  • Svenja Neumann

  • Heinz A. Horst

  • Albrecht Reichle

  • Reinhard Marks

  • Christoph Faul

Medical Centers

  • Department of Hematology/Oncology, Goethe-University Hospital Frankfurt, Frankfurt Am Main, Germany

  • Comprehensive Cancer Center Mainfranken and Department of Internal Medicine II, Division of Hematology and Medical Oncology, Wuerzburg, Germany

  • Department of Medicine II, University of Wuerzburg, Wuerzburg, Germany

  • Department for Internal Medicine II, Devision of Hematology and Medical Oncology, Wuerzburg University Medical Center, Wuerzburg, Germany

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital, Frankfurt, Germany

  • Medical Department II, University Medical Center of Schleswig-Holstein Kiel, Kiel, Germany

  • Department of Radiation Oncology, University Hospital Tubingen, Tuebingen, Germany

  • Campus Kiel, nd Dept. of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany

  • Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany

  • Department of Medicine A / Hematology and Oncology, University of Muenster, Muenster, Germany

  • Dpt. for Radiation Oncology, University of Regensburg, Regensburg, Germany

Locations

  • Germany

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute lymphoblastic leukemia

  • Cytokine release syndrome

  • Encephalopathy

Biomarkers

  • Breakpoint Cluster Region

  • Cytokine

  • Twist-related protein 1

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Blinatumomab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved